(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 3.99% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.02%.
Novartis Ag's revenue in 2026 is $56,372,000,000.On average, 26 Wall Street analysts forecast NVS's revenue for 2026 to be $111,892,896,000,000, with the lowest NVS revenue forecast at $102,272,526,000,000, and the highest NVS revenue forecast at $118,863,090,000,000. On average, 23 Wall Street analysts forecast NVS's revenue for 2027 to be $116,524,926,000,000, with the lowest NVS revenue forecast at $97,582,716,000,000, and the highest NVS revenue forecast at $126,058,626,000,000.
In 2028, NVS is forecast to generate $122,740,128,000,000 in revenue, with the lowest revenue forecast at $108,152,604,000,000 and the highest revenue forecast at $139,401,954,000,000.